We recently caught up with David Spigel from the Sarah Cannon Research Institute/Tennessee Oncology (TN, USA) to learn about the CheckMate-153 data he presented at the ESMO Congress (8–12th September, Madrid, Spain). Data from this study demonstrated that in patients with previously treated advanced non-small cell lung cancer, superior progression-free survival was induced with continuous treatment with nivolumab until disease progression compared with a 1 year fixed duration treatment.

More on nivolumab:

Nivolumab, ipilimumab combination succeeds in Phase III lung cancer trial

Immunotherapy nivolumab given the green light by NICE for NSCLCs

Patient selection for anti-PD-1/PD-L1 therapy in advanced NSCLC: implications for clinical practice

You might also like